16:30 , Aug 18, 2017 |  BC Week In Review  |  Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...
22:53 , Aug 11, 2017 |  BC Extra  |  Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...
07:00 , May 26, 2016 |  BC Innovations  |  Product R&D

H is for cancer

Letting the immune system do the heavy work, a group at Duke University has developed a cancer-killing antibody by studying the blood of atypical lung cancer patients with a slowly progressive form of the disease....
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Great Basin sales and marketing update

Great Basin launched its Portrait GBS Assay in U.S. hospitals and laboratories and in more than 32 countries accepting the CE-IVD Mark to detect Group B Streptococcus infection. The automated assay targets a highly...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Portrait GBS Assay regulatory update

FDA granted 510(k) clearance for Great Basin’s Portrait GBS Assay to detect group B Streptococcus infection from rectovaginal swabs. Great Basin plans to launch the assay in the U.S. this quarter. The automated assay runs...
07:00 , Aug 7, 2014 |  BC Innovations  |  Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

Lampalizumab: Additional Phase II data

Roche's Genentech Inc. unit disclosed the details of an exploratory biomarker from the single-blind Phase II MAHALO trial evaluating lampalizumab to treat GA associated with AMD. In August, data from 129 patients in MAHALO showed...
01:57 , Nov 19, 2013 |  BC Extra  |  Clinical News

Genentech details biomarkers for lampalizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) disclosed the details of an exploratory biomarker for the company's lampalizumab ( RG7417), which is in development to treat geographic atrophy (GA), an advanced form of dry...
08:00 , Feb 14, 2011 |  BioCentury  |  Strategy

Alexion's expansions

Alexion Pharmaceuticals Inc. last week laid out its plans for keeping up the momentum that has resulted in a doubling of market cap in the past year, from $4.1 billion on Feb. 12, 2010, to...
07:00 , Mar 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease ...